gdc
FDA Approvals, News & UpdatesLung Cancer

Tecentriq plus Chemotherapy Approved for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

April 2019 Vol 5 No 2

In March 2019, the FDA approved the use of the immunotherapy Tecentriq (atezolizumab; from Genentech), a PD-L1 inhibitor, in combination with a chemotherapy regimen as first-line treatment of patients with extensive-stage small-cell lung cancer. Tecentriq was previously approved for bladder (urothelial) cancer, non–small-cell lung cancer (or NSCLC), and in March 2019, for triple-negative breast cancer (read more).

This new approval was based on the results of a clinical trial of 403 patients who had not received chemotherapy for extensive-stage small-cell lung cancer. In this study, patients received either Tecentriq plus chemotherapy or placebo plus chemotherapy. The average survival was 3 months longer with the combination of immunotherapy plus chemotherapy, for a total of 12.3 months in the Tecentriq group versus 10.3 months in the placebo group. The average time without cancer progression was 5.2 months in patients who received Tecentriq plus chemotherapy versus 4.3 months in those who received placebo plus chemotherapy.

The most common side effects in the Tecentriq plus chemotherapy group were fatigue, nausea, hair loss (alopecia), constipation, and decreased appetite.

Recommended For You
COVID-19 (Coronavirus)Lung CancerWeb Exclusives
Updated Joint Statement on Coronavirus (COVID-19) from Lung Cancer Groups
LUNGevity and 4 other lung cancer organizations have provided information on the new coronavirus for people with lung cancer and other patients with cancer. This update also provides reliable sources of information for patients.
COVID-19 (Coronavirus)Lung CancerWeb Exclusives
COVID-19 FAQs for People with Lung Cancer
LUNGevity answers some frequently asked questions about patients with lung cancer and survivors and the coronavirus illness.
COVID-19 (Coronavirus)Lung Cancer
COVID-19 Conversation: Introduction
By Zosia Piotrowska, MD, MHS
In this series of videos from LUNGevity, oncologist Zosia Piotrowska, MD, MHS, Massachusetts General Hospital, Boston, addresses many of the questions and concerns raised in regard to coronavirus COVID-19 and patients with lung cancer.
COVID-19 (Coronavirus)Lung Cancer
COVID-19 Conversation: Part 1: About Coronavirus – COVID-19
By Zosia Piotrowska, MD, MHS
Oncologist Dr. Zosia Piotrowska addresses some specific questions about the impact of COVID-19. She discusses dealing with anxiety, symptoms, who is most at risk for the illness, how it is spread, how to avoid getting the illness, and the available treatments.
Last modified: June 3, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country